ANDA 90582, held by Sagent Pharms. Nafcillin Sodium.
As of Nov 16, 2026, ANDA 90582 (Nafcillin Sodium), held by Sagent Pharms, was first approved by FDA on Aug 24, 2012, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 24, 2012 | Original application | Approved | None posted |
| Nafcillin SodiumEQ 1GM BASE/VIAL · injectable;injection | Nafcillin Sodium | Rx |
| Nafcillin SodiumEQ 2GM BASE/VIAL · injectable;injection | Nafcillin Sodium | Rx |
| Feb 11, 2021 | Supplement 1Labeling · Standard review | Approved | None posted |
| Feb 11, 2021 | Supplement 3Labeling · Standard review | Approved | None posted |
| Feb 11, 2021 | Supplement 5Labeling · Standard review | Approved | None posted |
| Aug 24, 2012 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters